Compare · CORT vs NVO
CORT vs NVO
Side-by-side comparison of Corcept Therapeutics Incorporated (CORT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CORT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $184.18B, about 24.3x CORT ($7.58B).
- Both names hit the wire about 9 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 17 for CORT).
- Company
- Corcept Therapeutics Incorporated
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $7.58B
- $184.18B
- 1M return
- -
- +7.16%
- 1Y return
- -
- -14.17%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 9
- 9
- Recent ratings
- 17
- 25
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CORT
- ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
- Director Swisher Daniel N Jr exercised 1,500 shares at a strike of $13.13 and sold $111,105 worth of shares (1,500 units at $74.07) as part of a pre-agreed trading plan (SEC Form 4)
- Maduck Sean exercised 25,000 shares at a strike of $8.27 and sold $2,046,351 worth of shares (25,000 units at $81.85) as part of a pre-agreed trading plan (SEC Form 4)
- President, Oncology Vieira Roberto Wandenkolk exercised 8,333 shares at a strike of $21.63 and sold $674,069 worth of shares (8,333 units at $80.89) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Corcept Therapeutics Incorporated
- Corcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
- 2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S